(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Encephalopathy pipeline constitutes 70+ key companies continuously working towards developing 70+ Encephalopathy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Encephalopathy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
“Encephalopathy Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Encephalopathy Market.
Some of the key takeaways from the Encephalopathy Pipeline Report:
- Companies across the globe are diligently working toward developing novel Encephalopathy treatment therapies with a considerable amount of success over the years.
- Encephalopathy companies working in the treatment market are CAMP4 Therapeutics, LifeSplice, Encoded Therapeutics, CuroNZ, Cerecin, Longboard Pharmaceuticals, Neurocrine Biosciences, Vedanta Biosciences, PTC Therapeutics, Xenon Pharmaceuticals Inc., Amzell, and others are developing therapies for the Encephalopathy treatment
- Emerging Encephalopathy therapies in the different phases of clinical trials are- MP-SCN, SP-SCN8, ETX101, NRP 2945, Tricaprilin, LP352, NBI-921352, VE303, Vatiquinone, XEN496, AMZ 002, and others are expected to have a significant impact on the Encephalopathy market in the coming years.
- In June 2022, ReAlta Life Sciences revealed that the Fast Track designation for treating hypoxic ischemic encephalopathy (HIE) has been granted by the US Food and Drug Administration (FDA) to RLS-0071. This medication stands as the company’s primary dual-action complement inhibitor and innate anti-inflammatory peptide. Additionally, in March 2022, the US FDA approved an Investigational New Drug (IND) application for the Phase II clinical trial of RLS-0071.
- The primary MRT drug platform product, RBX2660, has been designed to target the treatment of various conditions such as Clostridium difficile (C.diff), ulcerative colitis, hepatic encephalopathy, and multi-drug resistant organisms. Rebiotix has obtained U.S. Patent No. 9,433,651 from the United States Patent and Trademark Office (USPTO) for its patent application titled “Microbiota Restoration Therapy (MRT), Compositions and Methods of Manufacture.” This patent encompasses Microbiota Restoration Therapy (MRT) compositions and methods pertaining to their manufacturing, processing, and delivery. It further extends Rebiotix’s existing patent issuances in Australia and Canada.
- PRAX-562 represents a pioneering preferential persistent sodium channel blocker currently under development to address a diverse spectrum of rare central nervous system (CNS) disorders. These encompass rare adult cephalgias along with developmental and epileptic encephalopathy. The US Food and Drug Administration (FDA) awarded orphan drug designation to PRAX-562 in April 2021 for the treatment of SCN2A developmental and epileptic encephalopathy (SCN2A-DEE). Additionally, in January 2021, the FDA granted rare pediatric disease designation for PRAX-562, intended for treating both SCN2A-DEE and SCN8A developmental and epileptic encephalopathy (SCN8A-DEE).
- In August 2021, Vyant Bio, Inc., and Cyclica, Inc., have declared a non-exclusive strategic partnership that merges Vyant Bio’s patient-derived complex organoid biology with Cyclica’s Artificial Intelligence (AI)-powered discovery platform spanning the proteome. The collaboration aims to uncover novel treatments for CDKL5 Deficiency Disorder (CDD), a severe neurodevelopmental epilepsy condition currently lacking effective treatments or a cure.
- In March 2021, Xenon Pharmaceuticals Inc. has commenced a Phase III study evaluating Adjunctive XEN496 in Pediatric Subjects diagnosed with KCNQ2 Developmental and Epileptic Encephalopathy. This trial aims to explore the potential antiseizure effects of adjunctive XEN496 (ezogabine) in comparison to a placebo among children diagnosed with KCNQ2 Developmental and Epileptic Encephalopathy (KCNQ2-DEE).
- Mallinckrodt Pharmaceuticals has created Vecamyl (mecamylamine hydrochloride) tablets, an oral medication designed to alleviate symptoms associated with Hepatic Encephalopathy (HE). These symptoms commonly include confusion, irritability, and restlessness. The medication operates by inhibiting the action of acetylcholine, a neurotransmitter crucially involved in the manifestation of HE symptoms.
- GSK has formulated lactulose, a synthetic sugar widely employed in treating Hepatic Encephalopathy (HE). Lactulose functions by reducing the levels of ammonia in the intestines, thereby aiding in the prevention of HE onset and providing relief from its associated symptoms.
Encephalopathy Overview
An encephalopathy is an illness, sickness, or damage to the brain. The phrase describes either short-term or long-term disorders that impact the structure or operation of the brain. Reversible and irreversible encephalopathies are the two primary forms.
Get a Free Sample PDF Report to know more about Encephalopathy Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/encephalopathy-pipeline-insight
Emerging Encephalopathy Drugs Under Different Phases of Clinical Development Include:
- MP-SCN: CAMP4 Therapeutics
- SP-SCN8: LifeSplice
- ETX101: Encoded Therapeutics
- NRP 2945: CuroNZ
- Tricaprilin: Cerecin
- LP352: Longboard Pharmaceuticals
- NBI-921352: Neurocrine Biosciences
- VE303: Vedanta Biosciences
- Vatiquinone: PTC Therapeutics
- XEN496: Xenon Pharmaceuticals Inc.
- AMZ 002: Amzell
Encephalopathy Route of Administration
Encephalopathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
- Intra-articular
- Intraocular
- Intrathecal
- Intravenous
- Ophthalmic
- Oral
- Parenteral
- Subcutaneous
- Topical
- Transdermal
Encephalopathy Molecule Type
Encephalopathy Products have been categorized under various Molecule types, such as
- Oligonucleotide
- Peptide
- Small molecule
Encephalopathy Pipeline Therapeutics Assessment
- Encephalopathy Assessment by Product Type
- Encephalopathy By Stage and Product Type
- Encephalopathy Assessment by Route of Administration
- Encephalopathy By Stage and Route of Administration
- Encephalopathy Assessment by Molecule Type
- Encephalopathy by Stage and Molecule Type
DelveInsight’s Encephalopathy Report covers around 70+ products under different phases of clinical development like
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Further Encephalopathy product details are provided in the report. Download the Encephalopathy pipeline report to learn more about the emerging Encephalopathy therapies
Some of the key companies in the Encephalopathy Therapeutics Market include:
Key companies developing therapies for Encephalopathy are – Mallinckrodt Pharmaceuticals, Salix Pharmaceuticals, GlaxoSmithKline plc., Pfizer Inc., ASKA Pharmaceutical Co., Ltd., Bausch Health, Johnson & Johnson Services, Inc., Janssen Global Services, Takeda Pharmaceutical Company Limited, Merck & Co., Inc., and others.
Encephalopathy Pipeline Analysis:
The Encephalopathy pipeline report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Encephalopathy with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Encephalopathy Treatment.
- Encephalopathy key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Encephalopathy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Encephalopathy market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Encephalopathy drugs and therapies
Encephalopathy Pipeline Market Drivers
- Increasing research & Development activities, continuous development of technology offering therapies for the treatment of various complications are some of the important factors that are fueling the Encephalopathy Market.
Encephalopathy Pipeline Market Barriers
- However, high cost of treatment, poor diagnosis in terms of the type of Encephalopathy and other factors are creating obstacles in the Encephalopathy Market growth.
Scope of Encephalopathy Pipeline Drug Insight
- Coverage: Global
- Key Encephalopathy Companies: CAMP4 Therapeutics, LifeSplice, Encoded Therapeutics, CuroNZ, Cerecin, Longboard Pharmaceuticals, Neurocrine Biosciences, Vedanta Biosciences, PTC Therapeutics, Xenon Pharmaceuticals Inc., Amzell, and others
- Key Encephalopathy Therapies: MP-SCN, SP-SCN8, ETX101, NRP 2945, Tricaprilin, LP352, NBI-921352, VE303, Vatiquinone, XEN496, AMZ 002, and others
- Encephalopathy Therapeutic Assessment: Encephalopathy current marketed and Encephalopathy emerging therapies
- Encephalopathy Market Dynamics: Encephalopathy market drivers and Encephalopathy market barriers
Request for Sample PDF Report for Encephalopathy Pipeline Assessment and clinical trials
Table of Contents
1. Encephalopathy Report Introduction
2. Encephalopathy Executive Summary
3. Encephalopathy Overview
4. Encephalopathy- Analytical Perspective In-depth Commercial Assessment
5. Encephalopathy Pipeline Therapeutics
6. Encephalopathy Late Stage Products (Phase II/III)
7. Encephalopathy Mid Stage Products (Phase II)
8. Encephalopathy Early Stage Products (Phase I)
9. Encephalopathy Preclinical Stage Products
10. Encephalopathy Therapeutics Assessment
11. Encephalopathy Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Encephalopathy Key Companies
14. Encephalopathy Key Products
15. Encephalopathy Unmet Needs
16 . Encephalopathy Market Drivers and Barriers
17. Encephalopathy Future Perspectives and Conclusion
18. Encephalopathy Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services
Press Release Distributed by ABNewswire.com
To view the original version on ABNewswire visit: Encephalopathy Pipeline Drugs Analysis Report (2023 Updates): FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Mallinckrodt Pharma, Salix Pharma, GlaxoSmithKline, Pfizer, ASKA
